Search results
Found 37873 matches for
Today, the University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
Catherine (Sassy) Molyneux
Principal Investigators
Catherine (Sassy) Molyneux - Professor of Global Health
Joel Tarning
MSc MGH Lecturers Principal Investigators
Joel Tarning - Professor of Clinical Pharmacology
Louise Thwaites
Clinical Consultants Principal Investigators
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Associate Professor
Rose McGready
Principal Investigators
Rose McGready - Professor of Tropical Maternal and Child Health
Peter Horby
Clinical Consultants Principal Investigators
FMedSci Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
Peijun Zhang
Principal Investigators
Peijun Zhang - Professor of Structural Biology and WELLCOME TRUST INVESTIGATOR
Anita Milicic
Principal Investigators
Associate Professor Anita Milicic - Group Leader, Vaccine Formulation and Adjuvants
Peter Ratcliffe
Clinical Consultants Principal Investigators
FRS Peter Ratcliffe - Professor of Clinical Medicine